Efficacy of the endothelin receptor blocker bosentan for refractory sickle cell leg ulcers

British Journal of Haematology

Volumn 142, Issue 6, 2008, Pages 991-992

  Lionnet, F ^a   Bachmeyer, C ^a   Stankovic, K ^a   Tharaux, P L ^a   Girot, R ^a,b   Aractingi, S ^a  

^a ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^b INSERM   (France)

Author keywords

Bosentan; Endothelin; Leg ulcer; Sickle cell anaemia

Indexed keywords

BOSENTAN; CREATININE; HEMOGLOBIN; LACTATE DEHYDROGENASE;

ADULT; CASE REPORT; CREATININE BLOOD LEVEL; DRUG EFFICACY; DYSPNEA; FEMALE; HEART CATHETERIZATION; HEMOGLOBIN BLOOD LEVEL; HUMAN; LACTATE DEHYDROGENASE BLOOD LEVEL; LEG ULCER; LETTER; LUNG ARTERY PRESSURE; PRIORITY JOURNAL; PROTEINURIA; PULMONARY HYPERTENSION; SICKLE CELL ANEMIA; TRICUSPID VALVE REGURGITATION; ULCER HEALING; VISUAL ANALOG SCALE; WOUND HEALING;

ANEMIA, SICKLE CELL; ANTIHYPERTENSIVE AGENTS; FEMALE; HUMANS; LEG ULCER; MIDDLE AGED; RECEPTORS, ENDOTHELIN; SULFONAMIDES;

EID: 50049085518     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/j.1365-2141.2008.07206.x     Document Type: Letter

References (7)

1. De Castro, L.M., Jonassaint, J.C., Graham, F.L., Ashley-Koch, A. Telen, M.J. (2008) Pulmonary hypertension associated with sickle cell disease: clinical and laboratory endpoints and disease outcomes. American Journal of Hematology, 83, 19 25.
2. Garcia de la Peña-Lefebvre, P., Rodriguez Rubio, S., Valero Expósito, M., Carmona, L., Gámir, M.L., Beltrán Gutiérrez, J., Diaz-Miguel, C., Orte Martinez, J. Zea Mendoza, A.C. (2008) Long term experience of bosentan for treating ulcers and healed ulcers in systemic sclerosis patients. Rheumatology (Oxford), 47, 464 466.
3. Halabi-Tawil, M., Lionnet, F., Girot, R., Bachmeyer, C., Levy, P.P. Aractingi, S. (2008) Sickle cell leg ulcers: a frequently disabling complication and a marker of severity. British Journal of Dermatology, 158, 339 344.
4. Hebbel, R. Vercelloti, G.M. (1997) The endothelial biology of sickle cell disease. The Journal of Laboratory and Clinical Medicine, 129, 288 293.
5. Kato, G.J., McGowan, V., Machado, R.F., Little, J.A., Taylor, J., Morris, C.R., Nichols, J.S., Wang, X., Poljakovic, M., Morris, S.M. Gladwin, M.T. (2006) Lactate dehydrogenase as a biomarker of hemolysis-associated nitric oxide resistance, priapism, leg ulceration, pulmonary hypertension, and death in patients with sickle cell disease. Blood, 107, 2279 2285.
6. Reiter, C.D., Wang, X.D., Tanus-Santos, J.E., Hogg, N., Cannon, R., Schechter, A.N. Gladwin, M.T. (2002) Cell-free hemoglobin limits nitric oxide bioavailability in sickle cell disease. Nature Medicine, 8, 1383 1389.
7. Tharaux, P.L., Hagège, I., Placier, S., Vayssairat, M., Kanfer, A., Girot, R. Dussaule, J.C. (2005) Urinary endothelin-1 as a marker of renal damage in sickle cell disease. Nephrology, Dialysis, Transplantation, 20, 2408 2413.